Targeting cholesterol-rich microdomains to circumvent tamoxifen-resistant breast cancer

Breast Cancer Research

Volumn 13, Issue 6, 2011, Pages

  Tiwary, Richa ^a   Yu, Weiping ^a   deGraffenried, Linda A ^b   Sanders, Bob G ^a   Kline, Kimberly ^b  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^b The University of Texas at Austin   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL ETHER LINKED ACETIC ACID; ANTINEOPLASTIC AGENT; CHOLESTEROL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR ALPHA; GROWTH FACTOR RECEPTOR; LIPOCORTIN 5; MAMMALIAN TARGET OF RAPAMYCIN; METHYL BETA CYCLODEXTRIN; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE B; TAMOXIFEN; UNCLASSIFIED DRUG; ALPHA TOCOPHEROL; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; ANTIOXIDANT; BETA CYCLODEXTRIN DERIVATIVE; METHYL-BETA-CYCLODEXTRIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CELL MEMBRANE; CONTROLLED STUDY; DRUG TARGETING; ENDOPLASMIC RETICULUM STRESS; FLUORESCENCE; GENE AMPLIFICATION; HUMAN; HUMAN CELL; MITOCHONDRION; PROTEIN PHOSPHORYLATION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; WESTERN BLOTTING; BREAST TUMOR; CELL SURVIVAL; DRUG EFFECT; DRUG RESISTANCE; FEMALE; METABOLISM; TUMOR CELL LINE;

ALPHA-TOCOPHEROL; ANTINEOPLASTIC AGENTS, HORMONAL; ANTIOXIDANTS; APOPTOSIS; BETA-CYCLODEXTRINS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL SURVIVAL; CHOLESTEROL; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MEMBRANE MICRODOMAINS; SIGNAL TRANSDUCTION; TAMOXIFEN;

EID: 82055171862     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr3063     Document Type: Article

References (42)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics. CA Cancer J Clin 2010, 60:277-300. 10.3322/caac.20073, 20610543.
2. Fabian CJ. The what and how of aromatase inhibitors: hormonal agents for treatment and prevention of breast cancer. Clin Practice 2007, 12:2051-2063.
3. Lewis JS, Jordan VC. Selective estrogen receptor modulators (SERMs): mechanisms of anticarcinogenesis and drug resistance. Mutat Res 2005, 591:247-263. 10.1016/j.mrfmmm.2005.02.028, 16083919.
4. Musgrove EA, Sutherland RL. Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer 2009, 9:631-643. 10.1038/nrc2713, 19701242.
5. Hurvitz SA, Pietras RJ. Rational management of endocrine resistance in breast cancer: a comprehensive review of estrogen receptor biology, treatment options, and future directions. Cancer 2008, 113:2385-2397. 10.1002/cncr.23875, 18819158.
6. Clarke R, Liu MC, Bouker KB, Gu Z, Lee RY, Zhu Y, Skaar TC, Gomez B, O'Brien K, Wang Y, Hilakivi-Clarke LA. Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling. Oncogene 2003, 22:7316-7339. 10.1038/sj.onc.1206937, 14576841.
7. Arpino G, Wiechmann L, Osborne CK, Schiff R. Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance. Endocr Rev 2008, 29:217-233. 2528847, 18216219.
8. Shou J, Massarweh S, Osborne CK, Wakeling AE, Ali S, Weiss H, Schiff R. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst 2004, 96:926-935. 10.1093/jnci/djh166, 15199112.
9. Li YC, Park MJ, Ye SY, Kim CW, Kim YN. Elevated levels of cholesterol-rich lipid rafts in cancer cells are correlated with apoptosis sensitivity induced by cholesterol-depleting agents. Am J Pathol 2006, 168:1107-1118. 10.2353/ajpath.2006.050959, 1606567, 16565487.
10. Patra SK. Dissecting lipid raft facilitated cell signaling pathways in cancer. Biochim Biophys Acta 2008, 1785:182-206.
11. Hoessli DC, Ilangumaran S, Soltermann A, Robinson PJ, Borisch B, Nasir-Ud-Din Signaling through sphingolipid microdomains of the plasma membrane: the concept of signaling platform. Glycoconj J 2000, 17:191-197. 10.1023/A:1026585006064, 11201790, Hoessli DC, Ilangumaran S, Soltermann A, Robinson PJ, Borisch B, Nasir-Ud-Din.
12. Latimer P, Menchaca M, Snyder RM, Yu W, Gilbert BE, Sanders BG, Kline K. Aerosol delivery of liposomal formulated paclitaxel and vitamin E analog reduces murine mammary tumor burden and metastases. Exp Biol Med 2009, 234:1244-1252.
13. Jia L, Yu W, Wang P, Sanders BG, Kline K. In vivo and in vitro studies of anticancer actions of alpha-TEA for human prostate cancer cells. Prostate 2008, 68:849-860. 10.1002/pros.20750, 18324647.
14. Shun MC, Yu W, Gapor A, Parsons R, Atkinson J, Sanders BG, Kline K. Pro-apoptotic mechanisms of action of a novel vitamin E analog (alpha-TEA) and a naturally occurring form of vitamin E (delta-tocotrienol) in MDA-MB-435 human breast cancer cells. Nutr Cancer 2004, 48:95-105. 10.1207/s15327914nc4801_13, 15203383.
15. Anderson K, Lawson KA, Simmons-Menchaca M, Sun L, Sanders BG, Kline K. Alpha-TEA plus cisplatin reduces human cisplatin-resistant ovarian cancer cell tumor burden and metastasis. Exp Biol Med 2004, 229:1169-1176.
16. Lawson KA, Anderson K, Menchaca M, Atkinson J, Sun L, Knight V, Gilbert BE, Conti C, Sanders BG, Kline K. Novel vitamin E analogue decreases syngeneic mouse mammary tumor burden and reduces lung metastasis. Mol Cancer Ther 2003, 2:437-444.
17. Hahn T, Fried K, Hurley LH, Akporiaye ET. Orally active α-tocopheryloxyacetic acid suppresses tumor growth and multiplicity of spontaneous murine breast cancer. Mol Cancer Ther 2009, 8:1570-1578. 10.1158/1535-7163.MCT-08-1079, 19509249.
18. Tiwary R, Yu W, Li J, Park SK, Sanders BG, Kline K. Role of endoplasmic reticulum stress in alpha-TEA mediated TRAIL/DR5 death receptor dependent apoptosis. PLoS One 2010, 5:e11865. 10.1371/journal.pone.0011865, 2912340, 20686688.
19. Shun MC, Yu W, Park SK, Sanders BG, Kline K. Downregulation of epidermal growth factor receptor expression contributes to alpha-TEA's proapoptotic effects in human ovarian cancer cell lines. J Oncol 2010, 2010:824571. 2833311, 20224651.
20. Tiwary R, Yu W, Sanders BG, Kline K. α-TEA cooperates with MEK or mTOR inhibitors to induce apoptosis via targeting IRS/PI3K pathways. Br J Cancer 2011, 104:101-109. 10.1038/sj.bjc.6606019, 3039802, 21119656.
21. Yu W, Tiwary R, Li J, Park SK, Jia L, Xiong A, Simmons-Menchaca M, Sanders BG, Kline K. α-TEA induces apoptosis of human breast cancer cells via activation of TRAIL/DR5 death receptor pathway. Mol Carcinog 2010, 49:964-973. 10.1002/mc.20681, 20886583.
22. Jia L, Yu W, Wang P, Li J, Sanders BG, Kline K. Critical roles for JNK, c-Jun, and Fas/FasL-signaling in vitamin E analog-induced apoptosis in human prostate cancer cells. Prostate 2008, 68:427-441. 10.1002/pros.20716, 18196534.
23. Wang P, Yu W, Hu Z, Jia L, Iyer VR, Sanders BG, Kline K. Involvement of JNK/p73/NOXA in vitamin E analog-induced apoptosis of human breast cancer cells. Mol Carcinog 2008, 47:436-445. 10.1002/mc.20400, 18058804.
24. Kline K, Lawson KA, Yu W, Sanders BG. Vitamin E and cancer. Vitam Horm 2007, 76:435-461.
25. Hahn T, Jagadish B, Mash EA, Garrison K, Akporiaye ET. α-Tocopheryloxyacetic acid: a novel chemotherapeutic that stimulates the antitumor immune response. Breast Cancer Res 2011, 13:R4. 10.1186/bcr2808, 3109570, 21232138.
26. Jayo A, Conde I, Lastres P, Martínez C, Rivera J, Vicente V, González-Manchón C. L718P mutation in the membrane-proximal cytoplasmic tail of beta 3 promotes abnormal alpha IIb beta 3 clustering and lipid microdomain coalescence, and associates with a thrombasthenia-like phenotype. Haematologica 2010, 95:1158-1166. 10.3324/haematol.2009.018572, 2895041, 20081061.
27. Beknke O, Tranum-Jensen J, van Deurs B. Filipin as a cholesterol probe. I. Morphology of filipin-cholesterol interaction in lipid model systems. Eur J Cell Biol 1984, 35:189-199.
28. Chou T-C. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res 2010, 70:440-446. 10.1158/0008-5472.CAN-09-1947, 20068163.
29. Pike LJ. Lipid rafts: bringing order to chaos. J Lipid Res 2003, 44:655-667. 10.1194/jlr.R200021-JLR200, 12562849.
30. Massarweh S, Schiff R. Resistance to endocrine therapy in breast cancer: exploiting estrogen receptor/growth factor signaling crosstalk. Endocr Relat Cancer Suppl 2006, 1:S15-S24.
31. Ghayad SE, Vendrell JA, Larbi SB, Dumontet C, Bieche I, Cohen PA. Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways. Int J Cancer 2010, 126:545-562. 10.1002/ijc.24750, 19609946.
32. deGraffenried LA, Friedrichs WE, Russell DH, Donzis EJ, Middleton AK, Silva JM, Roth RA, Hidalgo M. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity. Clin Cancer Res 2004, 10:8059-8067. 10.1158/1078-0432.CCR-04-0035, 15585641.
33. Leary AF, Drury S, Detre S, Pancholi S, Lykkesfeldt AE, Martin LA, Dowsett M, Johnston SR. Lapatinib restores hormone sensitivity with differential effects on estrogen receptor signaling in cell models of human epidermal growth factor receptor 2-negative breast cancer with acquired endocrine resistance. Clin Cancer Res 2010, 16:1486-1497. 10.1158/1078-0432.CCR-09-1764, 20179226.
34. Chu I, Blackwell K, Chen S, Slingerland J. The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer. Cancer Res 2005, 65:18-25.
35. Nahta R, Esteva FJ. Herceptin: mechanisms of action and resistance. Cancer Lett 2006, 232:123-138. 10.1016/j.canlet.2005.01.041, 16458110.
36. Ferrer-Soler L, Vazquez-Martin A, Brunet J, Menendez JA, De Llorens R, Colomer R. An update of the mechanisms of resistance to EGFR-tyrosine kinase inhibitors in breast cancer: gefitinib (Iressa)-induced changes in the expression and nucleo-cytoplasmic trafficking of HER-ligands. Int J Mol Med 2007, 20:3-10.
37. Pike LJ. Growth factor receptors, lipid rafts and caveolae: an evolving story. Biochim Biophys Acta 2005, 1746:260-273. 10.1016/j.bbamcr.2005.05.005, 15951036.
38. Márquez DC, Chen HW, Curran EM, Welshons WV, Pietras RJ. Estrogen receptors in membrane lipid rafts and signal transduction in breast cancer. Mol Cell Endocrinol 2006, 246:91-100. 10.1016/j.mce.2005.11.020, 16388889.
39. Freeman MR, Cinar B, Lu ML. Membrane rafts as potential sites of nongenomic hormonal signaling in prostate cancer. Trends Endocrinol Metab 2005, 16:273-279. 10.1016/j.tem.2005.06.002, 16002302.
40. Li J, Yu W, Tiwary R, Park SK, Xiong A, Sanders BG, Kline K. α-TEA-induced death receptor dependent apoptosis involves activation of acid sphingomyelinase and elevated ceramide-enriched cell surface membranes. Cancer Cell Int 2010, 10:40. 10.1186/1475-2867-10-40, 2976739, 20974006.
41. Yu C, Alterman M, Dobrowsky RT. Ceramide displaces cholesterol from lipid rafts and decreases the association of the cholesterol binding protein caveolin-1. J Lipid Res 2005, 46:1678-1691. 10.1194/jlr.M500060-JLR200, 15863835.
42. Anderson K, Simmons-Menchaca M, Lawson KA, Atkinson J, Sanders BG, Kline K. Differential response of human ovarian cancer cells to induction of apoptosis by vitamin E succinate and vitamin E analogue, alpha-TEA. Cancer Res 2004, 64:4263-4269. 10.1158/0008-5472.CAN-03-2327, 15205340.